Dermatology product developer and JLabs graduate Sienna Biopharmaceuticals floated at the middle of its range having raised $86m in venture funding.
Sienna Biopharmaceuticals, a US-based dermatology product developer backed by pharmaceutical group Johnson & Johnson, has raised $65m in its initial public offering.
The company issued just over 4.33 million shares priced at $15.00 each, the mid-point of the IPO’s $14 to $16 range.
Sienna is developing topical medical dermatology and aesthetics products, and will spend $27m of the proceeds on advancing its lead product candidate, SNA-120, through phase 2b clinical trials. SNA-120 is a treatment for pruritus, an itch…
